CAS.NO: 204656-20-2

 

LIraglutide 3.0 can reduce glycosylated hemoglobin, and it has been shown to be beneficial to cardiovascular treatment in typeⅡ diabetic patients with atherosclerotic cardiovascular disease with coronary heart disease, ischemic stroke, and peripheral artery disease. 

 

Product Name	Liraglutide
Packing Specification	10g/100g/500g
Appearances	White or off-white powder
Activity: NLT 10Unit/mg	70%~130%
Content: 95.0%~105.0%	95.0%~105.0%
Bacterial Endotoxin	Less than 10 EU/mg
Residual HCP	NMT 10ng/mg
Residual Exogenous DNA	NMT 10ng/dose
Macromolecular Potein	NMT 0.7%
HPLC Purity	98.0%
Storage Conditions	-15℃ below, protected from light, sealed.

Liraglutide Application

Used to prepare liraglutide formula injection.

 

Liraglutide Insulin Recommended Method

LIraglutide treatment easy dissolved in acidic (pH < 2.5), neutral and alkaline conditions, and can be dissolved and clarified above pH7.0.

 

 Transport and Storage Stability

Transportation stability: It is transported in an ice pack to keep it active.

Storage stability: the product can be stored for at least 24 months at -15°C below.

 

Notice and Disclaimer

Pollution should be avoided during operation.

the product should not be used for diagnosis or treatment of animals or humans.

 

If you want to know more aboutLiraglutide in type 1 diabetes, please visit our website.

 

as a, we can offer kinds of Materials for sale, anything you need, please contact us.